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Essentials
• Whether or not dabigatran enhances the risk of myocardial infarction is under discussion.
• We measured platelet reactivity and thrombin receptor expression in dabigatran patients.
• Platelet reactivity and thrombin receptor expression is enhanced during dabigatran treatment.
• This should be considered when choosing the optimal direct oral anticoagulant for individuals.
Summary. Background: The direct oral anticoagulant (DOAC) dabigatran is a direct thrombin inhibitor. Its landmark trial, the RE-LY study, observed a trend towards a higher incidence of myocardial infarctions (MIs) in dabigatran-treated patients. Since then, there have been discussions on whether dabigatran increases the risk of MI. Objective: In this study, we aimed to assess platelet reactivity and platelet thrombin receptor expression in dabigatran-treated patients. Methods: We conducted a cross-sectional study in 13 hospitalized patients with planned initiation of dabigatran medication. Platelet reactivity was measured by light-transmission aggregometry and platelet thrombin receptor expression was measured by flow cytometry analysis. Results: Platelet reactivity was higher after initiation of dabigatran medication as compared with baseline (baseline 44 AE 24% vs. dabigatran 70 AE 25%). Accordingly, the density of both platelet thrombin receptors (protease activated receptor [PAR]-1 and PAR-4) on platelets increased during dabigatran treatment (PAR1, baseline 63 AE 11% vs. dabigatran 70 AE 10%; PAR4, baseline
Introduction
Dabigatran is a direct oral anticoagulant (DOAC). It is a direct inhibitor of thrombin and has been shown to be non-inferior to vitamin K antagonists in the prevention and treatment of thromboembolic disease [1, 2] . Additionally, dabigatran is currently the only DOAC with an approved specific antidote that reverses its anticoagulant effects within minutes. Idarucizumab is a monoclonal antibody that reverses the anticoagulant effects of dabigatran completely within minutes [3] . However, the landmark trial of dabigatran in patients with atrial fibrillation showed higher rates of myocardial infarction (MI) in dabigatran-treated patients (relative risk, 1.38; 95% confidence interval [CI], 1.0-1.91; as compared with warfarin) [1] . Since then, the question as to whether dabigatran increases risk of MI has been a controversial topic of discussion. It is well known that enhanced platelet reactivity is a strong and independent risk factor for ischemic events [4] . Therefore, we hypothesized that direct thrombin inhibition by dabigatran enhances thrombin receptor expression on platelets and consecutively increases platelet reactivity. Hence, we aimed to investigate platelet reactivity and thrombin receptor density on platelets of dabigatran-treated patients.
Methods
We conducted a cross-sectional analysis in 13 patients with indications for oral anticoagulation due to atrial fibrillation. Platelet reactivity and expression of the platelet thrombin receptors (protease activated receptor-1 [PAR-1] and protease activated receptor-4 [PAR-4]) were measured prior to the first intake of dabigatran and 12 h after the first intake. Eligibility criteria were: planned initiation of dabigatran treatment and informed consent. The only exclusion criterion was hemorrhagic diathesis. Platelet reactivity was measured using thrombin receptor activating peptide-induced, collagen-induced, arachidonic acid-induced and adenosine diphosphate (ADP)-induced light-transmission aggregometry. PAR-1 and PAR-4 expression on platelets was measured by flow cytometry analysis. Statistical analysis was conducted using GraphPad Prism software (GraphPad Software Inc, San Diego, CA, USA) and the SPSS© Software (New York, NY, USA). The Kolmogorov-Smirnov test, q-q plots and histograms were used to test normality of data distribution. Normally distributed data were tested using the paired t-test. Non-normally distributed data were tested using the Wilcoxon matched pairs test. Data are mean AE standard deviation and mean difference with 95% CI. P values below 0.05 were considered significant. The study conformed to the Declaration of Helsinki and was approved by the University of D€ usseldorf Ethics Committee. Informed consent was obtained from all patients.
Results and discussion
Patients were 69 AE 11 years of age; 31% (four patients) were of male gender; 77% (10 patients) had a history of arterial hypertension; 8% (one patient) had diabetes mellitus; 31% (four patients) were current smokers (Table 1) . Four patients received 110 mg dabigatran and nine patients received 150 mg. Thrombin receptor activating peptide-induced platelet reactivity was higher after the first intake of dabigatran (prior 44 AE 24% vs. post 70 AE 25%, P = 0.005; mean difference, À25%; 95% CI, À9% to À41%) (Fig. 1A,B) . Correspondingly, the density of both platelet PAR receptors (PAR-1 and PAR-4) on patients' platelets was increased after initiation of dabigatran medication (PAR-1: prior 63 AE 11% vs. post 70 AE 10%, P < 0.0001, mean difference À7%, 95% CI À5% to -À 10%, Fig. 1C,D ; PAR-4: prior 1.1 AE 0.5% vs. post 1.6 AE 0.9%, P = 0.03; mean difference, À0.5%; 95% CI, À0.1% to À1%; not shown). Collagen, arachidonic acid and ADP-induced platelet reactivity did not change after initiation of dabigatran medication (collagen: prior 70 AE 20% vs. post 76 AE 24%, P = 0.48; mean difference, À7%; 95% CI, À28% to 14%; Fig. 2A ; arachidonic acid: prior 8 AE 6% vs. post 8 AE 4%, P = 0.97; mean difference, 0.1%; 95% CI, À4% to 4%; Fig. 2B ; ADP: prior 62 AE 25% vs. post 58 AE 33%, P = 0.65; mean difference, 4%; 95% CI, À15% to 23%; Fig. 2C ). Linear regression analysis revealed that thrombin-induced platelet aggregation was associated with platelet PAR-1 receptor density (beta = 0.41; 95% CI, 0.06 to 1.98; P = 0.04). Collagen, arachidonic acid and ADP-induced platelet aggregation was not associated with platelet PAR-1 receptor density (collagen: beta = 0.34; 95% CI, À1.2 to 1.6; P = 0.09; arachidonic acid: beta = 0.03; 95% CI, À0.18 to 0.21; P = 0.84; ADP: beta = 0.22; 95% CI, À0.5 to 1.66; P = 0.28). PAR-4 receptor density was not associated with platelet aggregation (thrombin: beta = 0.37; 95% CI, À0.9 to 26; P = 0.07; collagen: beta = 0.22; 95% CI, À6.7 to 17; P = 0.38; arachidonic acid: beta = 0.29; 95% CI, À0.75 to 4.4; P = 0.16; ADP: beta = 0.31; 95% CI, À3.3 to 25; P = 0.13).
The major finding of this study was that dabigatran medication increased platelet reactivity by enhancing thrombin receptor density on thrombocytes. The RE-LY study was the pivotal trial of dabigatran in patients with atrial fibrillation. 110 mg dabigatran showed similar efficacy in preventing stroke and systemic embolism with fewer rates of major hemorrhage as compared with vitamin k antagonist. Lower rates of stroke and systemic embolism with a similar incidence of major hemorrhage were observed using 150 mg dabigatran. However, both doses of dabigatran were associated with higher rates of MI [1] . The possibility that dabigatran medication increases the risk of MI has been discussed. In this study, we were able to demonstrate that dabigatran medication leads to enhanced thrombininduced platelet reactivity (Fig. 1) . Furthermore, it is well known that platelet reactivity is associated with the incidence of MI [5] . Platelet reactivity induced by collagen, arachidonic acid and ADP was not altered by dabigatran medication (Fig. 2) . Therefore, this observed enhanced platelet reactivity induced by thrombin receptor activating 
